Telos Capital Management’s Novartis NVS Stock Holding History

Telos Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.99M	Sell	25,483 -220	-0.9%	-$33K	0.35%	82
2026 Q1	$3.93M	Sell	25,703 -590	-2%	-$90.4K	0.38%	83
2025 Q4	$3.62M	Sell	26,293 -379	-1%	-$49.6K	0.34%	85
2025 Q3	$3.42M	Sell	26,672 -18	-0.1%	-$2.2K	0.33%	84
2025 Q2	$3.23M	Sell	26,690 -748	-3%	-$84.3K	0.33%	86
2025 Q1	$3.06M	Sell	27,438 -248	-0.9%	-$26.4K	0.33%	89
2024 Q4	$2.69M	Buy	27,686 +1,039	+4%	+$111K	0.29%	89
2024 Q3	$3.06M	Sell	26,647 -430	-2%	-$48.8K	0.32%	85
2024 Q2	$2.88M	Buy	27,077 +652	+2%	+$65.4K	0.32%	84
2024 Q1	$2.56M	Sell	26,425 -554	-2%	-$56.8K	0.29%	86
2023 Q4	$2.72M	Buy	26,979 +860	+3%	+$83K	0.33%	82
2023 Q3	$2.66M	Sell	26,119 -455	-2%	-$46.2K	0.37%	75
2023 Q2	$2.68M	Sell	26,574 -762	-3%	-$76.2K	0.36%	78
2023 Q1	$2.51M	Buy	27,336 +187	+0.7%	+$16.3K	0.35%	79
2022 Q4	$2.46M	Buy	27,149 +2,713	+11%	+$229K	0.36%	80
2022 Q3	$1.86M	Buy	24,436 +1,230	+5%	+$102K	0.31%	89
2022 Q2	$1.96M	Buy	23,206 +710	+3%	+$62.3K	0.3%	91
2022 Q1	$1.97M	Sell	22,496 -220	-1%	-$19K	0.26%	95
2021 Q4	$1.99M	Buy	22,716 +193	+0.9%	+$16K	0.25%	91
2021 Q3	$1.84M	Sell	22,523 -785	-3%	-$70.6K	0.25%	96
2021 Q2	$2.13M	Sell	23,308 -26,128	-53%	-$2.33M	0.28%	93
2021 Q1	$4.23M	Buy	49,436 +432	+0.9%	+$38.8K	0.61%	58
2020 Q4	$4.63M	Buy	49,004 +1,340	+3%	+$117K	0.71%	49
2020 Q3	$4.14M	Buy	47,664 +914	+2%	+$79.2K	0.72%	52
2020 Q2	$4.08M	Buy	46,750 +1,857	+4%	+$160K	0.79%	41
2020 Q1	$3.7M	Buy	44,893 +586	+1%	+$52.3K	0.92%	34
2019 Q4	$4.2M	Buy	44,307 +3,641	+9%	+$327K	0.96%	40
2019 Q3	$3.53M	Buy	40,666 +944	+2%	+$84.8K	0.97%	38
2019 Q2	$3.63M	Sell	39,722 -4,184	-10%	-$354K	1.06%	31
2019 Q1	$3.78M	Buy	43,906 +592	+1%	+$47.5K	1.18%	26
2018 Q4	$3.33M	Buy	43,314 +1,294	+3%	+$101K	1.23%	24
2018 Q3	$3.24M	Buy	42,020 +583	+1%	+$43.1K	1.04%	32
2018 Q2	$2.81M	Buy	41,437 +878	+2%	+$60.6K	0.97%	39
2018 Q1	$2.94M	Buy	40,559 +341	+0.8%	+$26K	1.04%	33
2017 Q4	$3.03M	Buy	40,218 +1,523	+4%	+$115K	1.07%	32
2017 Q3	$2.98M	Buy	38,695 +541	+1%	+$40.9K	1.15%	26
2017 Q2	$2.85M	Buy	38,154 +2,547	+7%	+$181K	1.14%	26
2017 Q1	$2.37M	Buy	35,607 +3,021	+9%	+$201K	0.99%	39
2016 Q4	$2.13M	Buy	32,586 +1,990	+7%	+$129K	0.95%	42
2016 Q3	$2.17M	Buy	30,596 +1,256	+4%	+$91.5K	1.01%	38
2016 Q2	$2.17M	Buy	29,340 +1,742	+6%	+$120K	1.06%	33
2016 Q1	$1.79M	Buy	27,598 +3,860	+16%	+$263K	0.94%	40
2015 Q4	$1.83M	Buy	23,738 +366	+2%	+$29.1K	0.99%	37
2015 Q3	$1.93M	Sell	23,372 -7,589	-25%	-$675K	1.18%	28
2015 Q2	$2.73M	Buy	30,961 +925	+3%	+$84.9K	1.51%	12
2015 Q1	$2.65M	Sell	30,036 -1,077	-3%	-$95.5K	1.55%	12
2014 Q4	$2.58M	Buy	31,113 +1,752	+6%	+$145K	1.58%	11
2014 Q3	$2.48M	Buy	29,361 +770	+3%	+$62.3K	1.54%	11
2014 Q2	$2.32M	Buy	28,591 +864	+3%	+$68K	1.43%	12
2014 Q1	$2.11M	Sell	27,727 -1,401	-5%	-$102K	1.48%	11
2013 Q4	$2.1M	Sell	29,128 -592	-2%	-$41.2K	1.54%	11
2013 Q3	$2.04M	Sell	29,720 -34	-0.1%	-$2.25K	1.66%	12
2013 Q2	$1.89M	Buy	+29,754	New	+$1.94M	1.65%	14

Other funds holding NVS

Scharf Investments Los Gatos, California $3.03B AUM 7.75% 1-Year Est. Return

CPC

Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GGI

Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

MIM

Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Telos Capital Management's NVS Position: Q2 2026 in Review

Telos Capital Management reduced its Novartis (NVS) stake by 0.86% in Q2 2026, selling an estimated $33K and leaving 25,483 shares worth $3.99M. The position accounts for 0.35% of the portfolio, ranked #82.

Telos Capital Management first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.63M in Q4 2020. 530 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Telos Capital Management held 25,483 shares of Novartis worth $3.99M as of Q2 2026.
Telos Capital Management sold 220 Novartis shares in Q2 2026, an estimated $33K.
Novartis made up 0.35% of Telos Capital Management's portfolio in Q2 2026, its #82 holding.
Telos Capital Management first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
Telos Capital Management's Novartis position peaked at $4.63M in Q4 2020.
530 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Telos Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.